This is an online educational activity
Duration: 2 hours (90 minute video, 30 minute post-test & evaluation)
Available: March 12, 2020 – March 11, 2021
This information was originally presented and recorded at the December 2019 AMSUS Annual Meeting
View Full CE Statement and Disclosures
NOTE- To view the video you must establish a profile.
If you have completed CE/CME evaluations with AMSUS in the past please log in using the same email address as an existing user.
View Video and Complete Post-test
Continuing Education Information
This continuing education activity is provided through a collaboration between AMSUS and AffinityCE. This activity provides continuing education credit for physicians, physician assistants, nurses, nurse practitioners, psychologists, health care executives, dentists, and pharmacists, as well as providing a statement of participation for other attendees.
This presentation provides attendees with a foundational understanding of the current state of the Veteran Affairs (VA) Precision Oncology Program (POP). Prostate and lung cancer are two of the most frequently diagnosed cancers among Veterans. The goal of the VA POP is to utilize precision medicine to provide cancer treatment to our nation’s Veterans that is equivalent to or exceeds that which is provided by private and academic cancer centers. The VA POP seeks to improve outcomes, for Veterans with cancer, through collaboration across federal programs and partnerships with nonprofit organizations. The Applied Proteogenomics Organizational Learning and Outcomes (APOLLO), is tri-agency partnership with the Department of Defense (DoD), National Cancer Institute (NCI), and VA. The program enables oncologists to accurately tailor cancer care for individual patients based on the genes and proteins associated with their tumors.
The Prostate Cancer Foundation committed a $50M investment to VA to establish the Precision Oncology Program for Cancer of the Prostate (POPCaP) with the goal of increasing Veteran access to genetic sequencing and clinical trials via a hub-and-spoke model. Sanford Health has committed to investing $25M to VA to create the Pharmacogenomics Action for cancer SuRvivorship (PHASeR) program to provide testing to help VA providers prescribe the most appropriate medications at the right dose for cancer survivors. The POP will develop target cancer treatments for Veterans utilizing big data and artificial intelligence through the VA-Department of Energy (DOE) Big Data Initiative. The VA will utilize a phased approach to establish POP System of Excellence (SOE) beginning with prostate cancer with a vision of the SOE servicing all forms of cancer within the next 10 years.
At the conclusion of this session, participants will be able to:
- Demonstrate knowledge of the paradigm shift in cancer treatment for Veterans through Precision Oncology.
- Explain how the VA-Prostate Cancer Foundation partnership will establish a System of Excellence for Precision Oncology that will:
- Build critical data and evidence-based decision-making tools
- Expand VA genetic sequencing capabilities
- Enhance access to clinical trials
- Understand and describe the scope partner affiliations of the VA National Precision Oncology Program to include:
- Applied Proteogenomics Organizational Learning and Outcomes (APOLLO)
- Pharmacogenomics Action for Cancer Survivorship (PHASeR)
- Tele-oncology Program
- Describe VA strategy and future vision for cancer treatment through a Precision Oncology System of Excellence.
- Carolyn Clancy, M.D. Deputy Undersecretary for Health for Discovery, Education, & Affiliate Networks, Department of Veterans Affairs
- Michael Kelley, M.D. National Oncology Program Director, Department of Veterans Affairs
- Matthew Rettig, M.D. Chief, Division of Hematology-Oncology, Los Angeles Healthcare System, Department of Veterans Affairs Greater
Facilitator: Dr. Carolyn Clancy, M.D. Deputy Undersecretary for Health for Discovery, Education, & Affiliate Networks, Department of Veterans Affairs
- Rachel Ramoni, DMD, ScD, Chief Research and Development Officer, Department of Veterans Affairs
- Robert Bruce Montgomery, Staff Physician, Puget Sound Healthcare System, Department of Veterans Affairs, Professor of Medical Oncology, University of Washington
- Deborah Lafer Scher, Executive Advisor to the Secretary, VA Center for Strategic Partnerships
- Jonathon Simons, M.D., President and Chief Executive Officer, Prostate Cancer Foundation
Presentation will include:
Introduction and Overview “What we mean by Precision Oncology”- Dr. Clancy
Enhancing Access to Clinical Trials – Dr. Rettig
- Precision Oncology in Prostate Cancer
- Prostate Cancer Precision Clinical Trials
- Impact of MVP on Prostate Cancer Clinical Care
- Future Directions in Prostate Cancer Treatment and Research
VA National Precision Oncology – Dr. Kelley
- APOLLO – An Intra agency collaboration
- PHASeR – A Public-Private Partnership in Pharmacogenomics
- Transforming Oncology Care Delivery in VA
- Providing Veteran Access to Tele-oncology
- A Vision for the Future: Precision Oncology System of Excellence
Panel Discussion – Dr. Clancy
Panelists – Veteran (TBN), Dr. Montgomery Dr. Ramoni, Deborah Scher, Dr. Simons